Skip to main content
SpringerLink
Log in

Pharmakologie der Drang- und Belastungsharninkontinenz

  • Chapter
  • First Online:
Inkontinenz- und Deszensuschirurgie der Frau

Zusammenfassung

Die Harninkontinenz nimmt über die letzten Jahre stetig zu und wird zukünftig eine noch größere medizinische Herausforderung darstellen. Eine adäquate Therapie – je nach Art der Harninkontinenz – ist nur nach einer suffizienten Diagnostik möglich. Verschiedene Therapieoptionen (konservativ, medikamentös, operativ) kommen sequenziell und/oder kombiniert zum Einsatz. Dieses Kapitel informiert neben den pharmakotherapeutischen Ansatzpunkten über den aktuellen Stand der medikamentösen Therapie der Drang- und Belastungsinkontinenz. Aufgeschlüsselt nach der Wirkweise werden die verfügbaren Substanzen umfassend dargestellt. Ein Schwerpunkt ist die Relevanz der Substanzen im täglichen klinischen Alltag mit allen Vor- und Nachteilen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Armstrong RB, Luber KM, Peters KM (2005) Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int Urol Nephrol 37: 247–252

    Article  CAS  PubMed  Google Scholar 

  • Blue DR, Daniels DV, Gever JR, Jett MF, O’Yang C, Tang HM, Williams TJ, Ford AP (2004) Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int 93: 162–170

    Article  CAS  PubMed  Google Scholar 

  • Cartwright R, Cardozo L (2007) Transdermal oxybutynin: sticking to the facts. Eur Urol 51: 907–914

    Article  CAS  PubMed  Google Scholar 

  • Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C (2013) OnabotulinumtoxinA 100U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64: 249–56

    Article  CAS  PubMed  Google Scholar 

  • Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52: 1204–12.

    Article  CAS  PubMed  Google Scholar 

  • Chapple CR, Patroneva A, Raines SR (2006) Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol 49: 879–886

    Article  CAS  PubMed  Google Scholar 

  • Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A, YM-905 Study Group (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93: 303–310

    Google Scholar 

  • De Ridder D, Baert L (2000) Vanilloids and the overactive bladder. BJU Int 86: 172–180

    Article  CAS  PubMed  Google Scholar 

  • Dmochowski RR, Appell RA (2000) Advancements in pharmacologic management of the overactive bladder. Urology 56: 41–49

    Article  CAS  PubMed  Google Scholar 

  • Frohme C, Varga Z, Olbert P, Schrader AJ, Hofmann R, Hegele A (2010) Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis. Urologe A 49: 639–44

    Article  CAS  PubMed  Google Scholar 

  • Fuller RW, Hemrick-Luecke SK, Snoddy HD (1994) Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther 269: 132–136

    CAS  PubMed  Google Scholar 

  • Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC; Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group (2005) A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173: 1647–1653

    Article  CAS  PubMed  Google Scholar 

  • Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187: 2131–9

    Article  CAS  PubMed  Google Scholar 

  • Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL (2013) Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int 112: 373–85

    Article  CAS  PubMed  Google Scholar 

  • Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD (2006) Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 98: 1025–1032

    Article  CAS  PubMed  Google Scholar 

  • Hegele A, Frohme C, Varga Z, Olbert P, Kranz J, Hofmann R (2011) Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance. Urol Int 87: 439–44

    Article  CAS  PubMed  Google Scholar 

  • Hills CJ, Winter SA, Balfour JA (1998) Tolterodine. Drugs 55: 813–820

    Article  CAS  PubMed  Google Scholar 

  • Jost WH, Marsalek P, Michel MC (2005) Pharmacotherapy of stress incontinence. Dtsch Med Wochenschr 130: 2337–2342

    Article  CAS  PubMed  Google Scholar 

  • Kelleher CJ, Tubaro A, Wang JT, Kopp Z (2008) Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 102: 56–61

    Article  CAS  PubMed  Google Scholar 

  • Knippschild S, Frohme C, Olbert P, Hofmann R, Hegele A (2012) Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy. Urologe A 51: 379–83

    Article  CAS  PubMed  Google Scholar 

  • Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 93: 311–318

    Article  Google Scholar 

  • Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189: 1388–95

    Article  CAS  PubMed  Google Scholar 

  • Nitti VW, Dmochowski R, Herschom S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C: EMBARK Study Group (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189: 1286–93

    Google Scholar 

  • Robinson D, Cardozo LD (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62: 45–51

    Article  PubMed  Google Scholar 

  • Schurch B (2006) Botulinum toxin for the management of bladder dysfunction. Drugs 66: 1301–1318

    Article  CAS  PubMed  Google Scholar 

  • Schurch Bm Schmid DM, Stöhrer M (2000) Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342: 665

    Article  CAS  PubMed  Google Scholar 

  • Stohrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ; Propiverine Investigator Group (2007) Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, double-blind, multicenter clinical study. Eur Urol 51: 235–242

    Article  Google Scholar 

  • Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274: 1014–1024

    CAS  PubMed  Google Scholar 

  • Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19: 344–350

    Article  CAS  PubMed  Google Scholar 

  • Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF; Pelvic Floor Disorders Network (2012) Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med 367: 1803–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weiss JP, Jumadilova Z, Johnson TM 2nd, Fitzgerald MP, Carlsson M, Martire DL, Malhotra A (2013) Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol 189: 1396–401

    Article  CAS  PubMed  Google Scholar 

  • Zinner NR (2005) Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother 6: 1409–1420

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Gießen und Marburg GmbH – Standort Marburg, Baldingerstraße, 35033, Marburg, Deutschland

    A. Hegele

Authors
  1. A. Hegele
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Gießen und Marburg, Marburg, Germany

    Rainer Hofmann

  2. Klinik für Gynäkologie, Universitätsklinikum Gießen und Marburg, Marburg, Germany

    Uwe Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hegele, A. (2015). Pharmakologie der Drang- und Belastungsharninkontinenz. In: Hofmann, R., Wagner, U. (eds) Inkontinenz- und Deszensuschirurgie der Frau. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43671-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43671-4_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43670-7

  • Online ISBN: 978-3-662-43671-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation